The company plans to market pen injectors filled with the synthetic generic peptide in either 1.2-mililiter or 2.4-mililiter quantities.

The company also said it has resubmitted the new drug application for its dihydroergotamine injections for the treatment of migraine headaches to the US Food and Drug Administration.

Amneal shares recently were climbing 1% higher during after hours.

http://www.mtnewswires.com
Copyright © 2024 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.